PFIZER INC
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 28, 2026 | Aug 4, 2026 | Before market open | $15.03B | $-0.04 | $0.77 |
| Q1 FY2026 Ended Mar 29, 2026 | May 5, 2026 | Before market open | $14.50B | $0.47 | $0.75 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 3, 2026 | Before market open | $17.60B | $-0.29 | $0.66 |
| Q3 FY2025 Ended Sep 28, 2025 | Nov 4, 2025 | Before market open | $16.70B | $0.62 | $0.87 |
| Q2 FY2025 Ended Jun 29, 2025 | Aug 5, 2025 | Before market open | $14.70B | $0.51 | $0.78 |
| Q1 FY2025 Ended Mar 30, 2025 | Apr 29, 2025 | Before market open | $13.70B | $0.52 | $0.92 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 4, 2025 | Before market open | $17.80B | $0.07 | $0.63 |
| Q3 FY2024 Ended Sep 29, 2024 | Oct 29, 2024 | Before market open | $17.70B | $0.78 | $1.06 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 30, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted (3) diluted EPSnon-GAAP | full-year 2026 | $2.80 to $3.00 | Maintained |
| Adjusted (3) R&D Expensesnon-GAAP | 2026 | $10.50B to $11.50B | Lowered |
| Adjusted (3) SI&A Expensesnon-GAAP | 2026 | $12.50B to $13.50B | Raised |
| Effective Tax Rate on Adjusted (3) Incomenon-GAAP | 2026 | 15% | Maintained |
| Revenue | full-year 2026 | $60.50B to $62.50B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Pfizer filed with the SEC
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
Regulation FD disclosure · EX-99.1 to Form 8-K
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
Results of operations · Exit or restructuring costs · EX-99 to Form 8-K
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
Regulation FD disclosure · EX-99.1 to Form 8-K
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
Results of operations · EX-99 to Form 8-K
TSRUs represent an important retention tool for our colleagues, while aligning their interests with the interests of our shareholders by providing value tied to absolute total shareholder return.
Executive or director change · Other events · EX-99.1 to Form 8-K
shareholder return is negative for the performance period. All other terms of the 2022 and 2023 PSAs will remain unchanged.
Executive or director change · Other events · EX-99.2 to Form 8-K
Pfizer Reports First-Quarter 2024 Results
Results of operations · EX-99 to Form 8-K
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Results of operations · EX-99 to Form 8-K
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Other events · EX-99.1 to Form 8-K
Pfizer Completes Acquisition of Seagen
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Pfizer Completes Acquisition of Seagen
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pfizer Provides Full-Year 2024 Guidance
Regulation FD disclosure · EX-99.1 to Form 8-K
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pfizer Reports Third-Quarter 2023 Results
Results of operations · EX-99 to Form 8-K
Pfizer Amends U.S. Government Paxlovid Supply Agreement and
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99 to Form 8-K
Pfizer Reports Second-Quarter 2023 Results
Results of operations · EX-99 to Form 8-K
Pfizer Reports First-Quarter 2023 Results
Results of operations · EX-99 to Form 8-K
Pfizer Invests $43 Billion to Battle Cancer
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Breakthroughs that change patients’ lives 1
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
VOTING AGREEMENT (this “ Agreement ”), dated as of March 12, 2023, is by and among (i) Pfizer Inc., a Delaware corporation (“ Parent ”), (ii) Seagen Inc., a Delaware corporation (the “ Company ”),
Material agreement · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Results of operations · EX-99 to Form 8-K
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
Results of operations · EX-99 to Form 8-K
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Results of operations · EX-99 to Form 8-K